3.2 Hematopoiesis and Hemostasis

Hematopoiesis and Hemostasis

Blood formation and clotting are two processes that keep your cardiovascular system running. Hematopoiesis is how your body produces all blood cells from stem cells in the bone marrow. Hemostasis is how your body stops bleeding after an injury. Together, they maintain the right number of circulating blood cells and prevent you from losing blood when a vessel is damaged.

Hematopoiesis and Stem Cells

Hematopoiesis: Blood Cell Formation

Hematopoiesis is the production of blood cells, and in adults it happens primarily in the red bone marrow of flat bones (like the sternum, pelvis, and skull) and the epiphyses of long bones. This single process is responsible for generating all three types of formed elements:

• Erythrocytes (red blood cells) for oxygen transport
• Leukocytes (white blood cells) for immune defense
• Thrombocytes (platelets) for clotting

The whole system is regulated by cytokines, growth factors, and transcription factors that control whether blood cells survive, multiply, or mature into a specific type.

Hematopoietic Stem Cells (HSCs)

All blood cells trace back to a single cell type: the hematopoietic stem cell (HSC). HSCs are multipotent, meaning they can develop into many (but not all) cell types. They have two options at any given time:

1. Self-renew to maintain the stem cell pool so you never run out.
2. Differentiate into a progenitor cell that's committed to a specific lineage.

Early on, growth factors like stem cell factor (SCF) and interleukin-3 (IL-3) keep these progenitors alive and dividing. From there, HSCs branch into two major lineages:

• Common myeloid progenitor → gives rise to erythrocytes, platelets, and myeloblasts (which become granulocytes and monocytes)
• Common lymphoid progenitor → gives rise to lymphoblasts, which further differentiate into B cells and T cells

Lineage-Specific Hematopoiesis

Once a progenitor commits to a lineage, a specific growth factor drives its maturation:

• Erythropoiesis (RBC production): Regulated by erythropoietin (EPO), a hormone produced by the kidneys. When oxygen levels drop (hypoxia), the kidneys release more EPO to ramp up red blood cell production. This is a direct feedback loop: low oxygen → more EPO → more RBCs → improved oxygen delivery.
• Leukopoiesis (WBC production): Generates granulocytes (neutrophils, eosinophils, basophils), monocytes, and lymphocytes. Granulocyte colony-stimulating factor (G-CSF) specifically drives granulocyte differentiation and maturation.
• Thrombopoiesis (platelet production): Platelets bud off from large cells called megakaryocytes in the bone marrow. Thrombopoietin (TPO), produced mainly by the liver and kidneys, regulates this process.

Mechanisms of Hemostasis

Hemostasis keeps blood in a fluid state inside intact vessels but rapidly forms a clot when a vessel is damaged. It unfolds in three overlapping stages.

Stage 1: Vascular Spasm

The moment a blood vessel is damaged, smooth muscle in the vessel wall contracts. This vasoconstriction narrows the vessel and slows blood flow to the injured area. Endothelial cells release endothelin and thromboxane A₂ to trigger and sustain the spasm. By itself, vascular spasm won't stop bleeding, but it buys time for the next stages.

Stage 2: Platelet Plug Formation

Platelets circulate in an inactive state, but when the vessel lining breaks, they encounter exposed collagen and von Willebrand factor (vWF) in the subendothelium. Here's the sequence:

1. Adhesion: Platelets bind to collagen and vWF at the injury site.
2. Activation: Bound platelets change shape and release granules containing ADP, serotonin, and thromboxane A₂.
3. Aggregation: These chemical signals recruit more platelets to the site, which stick together to form a platelet plug.

This plug is enough to seal small breaks, but larger injuries need reinforcement from the coagulation cascade.

Stage 3: Coagulation Cascade

The coagulation cascade is a series of enzymatic reactions where each clotting factor activates the next, amplifying the response at every step. There are two initial pathways:

• Intrinsic pathway: Activated when blood contacts negatively charged surfaces (like exposed collagen). All factors needed are already present within the blood.
• Extrinsic pathway: Activated when damaged cells release tissue factor (factor III) into the blood. Called "extrinsic" because tissue factor comes from outside the blood.

Both pathways converge on the common pathway:

1. Factor X is activated (by either pathway).
2. Factor Xa converts prothrombin (factor II) into thrombin.
3. Thrombin converts soluble fibrinogen into insoluble fibrin strands.
4. Fibrin monomers polymerize into a mesh that reinforces the platelet plug.
5. Factor XIIIa cross-links the fibrin strands, stabilizing the clot.

Anticoagulation and Fibrinolysis

The cascade is tightly regulated to prevent clots from spreading beyond the injury. Key natural anticoagulants include:

• Antithrombin III: Inactivates thrombin and several other clotting factors.
• Protein C and Protein S: Work together to degrade factors Va and VIIIa, slowing the cascade.

Once healing is underway, the clot needs to be removed. Tissue plasminogen activator (tPA) and urokinase convert plasminogen into plasmin, which breaks down fibrin and dissolves the clot. This process is called fibrinolysis.

Regulation of Hematopoiesis and Hemostasis

Regulatory Factors in Hematopoiesis

Hematopoiesis is controlled at multiple levels:

• Early progenitors: SCF and IL-3 promote survival and proliferation of uncommitted stem cells.
• Lineage-specific growth factors: EPO (red blood cells), G-CSF (granulocytes), and TPO (platelets) each drive maturation of their respective cell type.
• Transcription factors: Proteins like GATA-1 and PU.1 act as molecular switches that commit a progenitor to a specific lineage. GATA-1 pushes cells toward the erythrocyte/megakaryocyte lineage, while PU.1 favors myeloid and lymphoid development.

These signals work together in a feedback system. For example, if your platelet count drops, the liver and kidneys increase TPO production, which stimulates megakaryocytes to produce more platelets.

Balance of Procoagulant and Anticoagulant Factors

Healthy hemostasis depends on a balance between factors that promote clotting and factors that prevent it. Tip too far in one direction and you get uncontrolled bleeding; tip the other way and you get dangerous clots.

Endothelial cells are central to this balance. An intact endothelial lining maintains a non-thrombogenic (anti-clotting) surface by producing thrombomodulin, which activates protein C. But when damaged, those same cells release tissue factor, which kicks off the extrinsic pathway. This dual role makes the endothelium the gatekeeper of hemostasis.

Disorders of Hematopoiesis and Hemostasis

Hematopoietic Disorders

When hematopoiesis goes wrong, the result is too few cells, dysfunctional cells, or uncontrolled cell growth:

• Aplastic anemia: The bone marrow fails to produce adequate blood cells. Causes include toxins, radiation, and autoimmune destruction of stem cells. Patients become anemic, infection-prone, and bleed easily because all three cell lines are affected.
• Myelodysplastic syndromes (MDS): The marrow produces blood cells, but they're abnormal and don't function properly (ineffective hematopoiesis). MDS carries an increased risk of progressing to acute myeloid leukemia (AML).
• Leukemias: Cancers of blood-forming tissue. AML involves uncontrolled proliferation of immature myeloid cells, while chronic lymphocytic leukemia (CLL) involves overproduction of mature-appearing but dysfunctional lymphocytes. In both cases, the abnormal cells crowd out normal blood cell production.

Hemostatic Disorders

Hemostatic disorders fall into two categories: excessive bleeding or inappropriate clotting.

Bleeding disorders:

• Hemophilia A: Inherited deficiency of clotting factor VIII. Hemophilia B is a deficiency of factor IX. Both cause prolonged bleeding, especially into joints and muscles.
• Von Willebrand disease: The most common inherited bleeding disorder. A deficiency or dysfunction of vWF impairs platelet adhesion, leading to prolonged bleeding time, particularly from mucosal surfaces.

Clotting (thrombotic) disorders:

• Deep vein thrombosis (DVT): A clot forms in a deep vein, usually in the leg. If it breaks loose and travels to the lungs, it becomes a pulmonary embolism (PE), which can be fatal.
• Factor V Leiden mutation: A genetic variant that makes factor V resistant to inactivation by protein C, increasing clot risk.
• Disseminated intravascular coagulation (DIC): A life-threatening condition where coagulation activates throughout the body. Microthrombi form in small vessels, consuming clotting factors and platelets. Paradoxically, this leads to both widespread clotting and severe bleeding at the same time, often with organ dysfunction.